ALIPAY+
Alipay+ has further strengthened its partnership with Asia’s largest food delivery platform, foodpanda, to Malaysia. Through this partnership, foodpanda Malaysia’s customers can now enjoy convenient food and grocery deliveries by paying through Touch ’n Go eWallet, one of the leading mobile wallets in Malaysia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005758/en/
Alipay+ has further strengthened its partnership with Asia’s largest food delivery platform, foodpanda, to Malaysia.
With contactless payments becoming more prevalent over the past few years, users of Touch ’n Go eWallet are now able to purchase food and daily essentials through foodpanda Malaysia, the country’s leading quick commerce delivery platform. Customers can also enjoy instant cash discount at checkout via Touch ‘n Go eWallet when placing orders on foodpanda.
“foodpanda Malaysia is committed to providing our customers with the convenience of having their food and daily essentials delivered right to their doorstep. We strive to be 1% better each time and add value to our customer’s experience. This time, it is to give them more options in payment methods,” said foodpanda Malaysia Chief Executive Officer Sayantan Das.
“We are proud to be partnering with Alipay+ and TNG Digital to enable the usage of Touch ’n Go eWallet on our platform. Leveraging our synergies as the leading quick commerce platform and the largest eWallet provider in the country, we are happy to play our role in encouraging the adoption of digital payment for the convenience and safety of millions of our merchants, riders and customers,” he added.
The gross merchandise value (GMV) of the on-demand food delivery market in Southeast Asia is expected to reach US$49.7 billion by 2030, growing at a compound annual growth rate of 14.1%, according to a 2022 report from research firm Frost & Sullivan. The GMV was estimated to be at US$15.2 billion in 2021, it said.
foodpanda Malaysia’s latest partnership with Touch ’n Go eWallet will tap into the eWallet’s more than 18 million registered users.
Commenting on the collaboration, Alan Ni, Chief Executive Officer of TNG Digital Sdn Bhd said, “We are very excited to partner with foodpanda to give our users access to a seamless and convenient delivery experience in Malaysia.
“Through Touch ’n Go eWallet, our users will be able to make payments for their orders with peace of mind knowing that their transactions are safe and secure,” he added.
Introduced by Ant Group in 2020, Alipay+ is a suite of cross-border digital payment, marketing and merchant digitization solutions connecting global brands with mobile-savvy consumers worldwide. Currently, 16 global e-wallet partners backed by Alipay+ have covered more than 1.3 billion digital-savvy consumers, mostly in Southeast Asia.
Alipay+ Rewards is a new digital marketing platform developed by Alipay+ and partner e-wallets to help global brands better engage with consumers worldwide by offering incentives and exclusive services.
Malaysia is the fifth major market in Asia where Alipay+ and foodpanda have collaborated to provide services with leading local mobile wallets in the region. Prior to this latest partnership in Malaysia, other Alipay+ partner e-wallets, including GCash in the Philippines, TrueMoney in Thailand, bKash in Bangladesh and AlipayHK in Hong Kong SAR, China, have already supported payments on their respective local foodpanda platforms.
Jing Yin, General Manager of Acquiring Service and Global Strategic Accounts of Ant Group, said: “Alipay+ is committed to helping merchants reach more than 1 billion global consumers and ensure easy and smooth payments of our e-wallet partners when consumers place orders on each platform.
“We are excited to offer payment and marketing solutions to foodpanda Malaysia through the Touch ’n Go eWallet, and we are looking forward to partnering with foodpanda in more markets by bringing more designated benefits with our local e-wallet partners in the future.”
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing solutions offered by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
About foodpanda
foodpanda is a leading delivery platform in Asia Pacific dedicated to bringing consumers a wide range of food, groceries and more, quickly and conveniently. Powered by technology and operational excellence, foodpanda is spearheading the growth of quick-commerce (q-commerce) across the region with its network of retail partners, as well as pandamart cloud stores to provide more on-demand options beyond the millions of food delivery options. foodpanda operates in more than 300 cities across 11 markets in Asia Pacific - Singapore, Hong Kong, Thailand, Malaysia, Pakistan, Taiwan, Philippines, Bangladesh, Laos, Cambodia, and Myanmar. foodpanda is a subsidiary of Delivery Hero, a global leader in the food delivery industry. For more information, visit www.foodpanda.com.
About TNG Digital Sdn Bhd
TNG Digital Sdn Bhd (“TNGD”) was founded by Touch ‘n Go Sdn Bhd and Ant Group (“Ant”), parent company of Alipay, China’s largest digital payments platform. Established in 2017, TNGD is the owner and operator of Touch ‘n Go eWallet, Malaysia’s number one eWallet company, with more than 18 million registered users and over 1.2 million merchant touch points including DuitNow QR. Combining Touch ‘n Go’s strong domestic brand, dominance in toll, transit and parking use cases and nationwide user base, together with Ant’s deep domain expertise and leading the development of open platforms for technology-driven inclusive financial services, the Touch ‘n Go eWallet provides financial services and payments services to both retail users and small to mid-sized businesses, across physical and online infrastructure. For more information, please visit www.touchngo.com.my.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005758/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom